What's in National Skin Centre's pipeline?

National Skin Centre has 2 drugs in our index: 1 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with National Skin Centre's portfolio?

Top competitors by shared drug class: Islamabad Medical and Dental College, Khyber Teaching Hospital.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/national-skin-centre.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

National Skin Centre — Portfolio Competitive Intelligence Brief

National Skin Centre pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Hydroquinone cream	Hydroquinone cream	marketed	Depigmenting agent	Tyrosinase	Dermatology
Eflornithine hydrochloride cream	Eflornithine hydrochloride cream	phase 3	Ornithine decarboxylase inhibitor	Ornithine decarboxylase (ODC)	Dermatology

Therapeutic area mix

Dermatology · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Islamabad Medical and Dental College · 1 shared drug class
Khyber Teaching Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for National Skin Centre:

Cite this brief

Drug Landscape (2026). National Skin Centre — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/national-skin-centre. Accessed 2026-05-16.